Study Overview
This study investigates the use of calcium dobesilate alongside ranibizumab injections to see if it can lower the number of treatments needed for patients with diabetic macular edema (DME) that affects vision.
Methods
The research involved 90 patients with DME. They were split into two groups: one group received both ranibizumab injections and calcium dobesilate capsules, while the other group received only the injections. Treatments were given monthly for three months, with follow-ups at 12 months to evaluate how often injections were needed, improvements in vision, and changes in macular thickness.
Results
After 12 months, patients who received the combination therapy needed fewer injections (average of 4.73) compared to those who only received ranibizumab (average of 6.02). This difference was significant. Both groups showed improvements in vision and macular thickness, but the combination therapy group had greater enhancements, indicating it was more effective in treating DME while reducing the need for injections.
Conclusion
The combination of calcium dobesilate and ranibizumab not only reduced the number of injections needed but also led to better improvements in vision and macular health compared to using ranibizumab alone. Both treatments were well-tolerated, showing a good safety profile.
Opportunities for Clinics and Patients
Based on the trial data, clinics can aim to:
- Reduce the frequency of injections for patients.
- Improve patient outcomes in vision and macular health.
Measurable Outcomes
Set clear goals for:
- Lowering the number of injections needed.
- Enhancing patient vision and comfort.
AI Tools for Clinical Needs
Select AI solutions that fit specific tasks related to managing DME treatments effectively.
Implementation Steps
Start with a pilot project to test the combination therapy, track results, and assess the real-world impact using AI solutions.
Contact Us for AI Solutions in Medical Management
For more information, reach out to us:
